Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

THE GOVERNMENT PHARMACEUTICAL ORGANIZATION

Home Clinical Trial Sponsors and OrganizationsTHE GOVERNMENT PHARMACEUTICAL ORGANIZATION

THE GOVERNMENT PHARMACEUTICAL ORGANIZATION

ACTIVE

75/1 Rama 6 Road, Ratchathewi, Bangkok, Thailandwww.intergpomed.comSubsidiary

Also known as:

gpo

Part of government of thailand

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

45

36 active

Approvals

8

Total approvals

Agencies

2

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

21

46.7%

Not Applicable

19

42.2%

Phase 2

3

6.7%

Phase 3

2

4.4%

Trial Status Distribution

Completed

7

15.6%

Enrolling By Invitation

1

2.2%

Not yet recruiting

35

77.8%

Unknown

2

4.4%

Clinical Trials

Trials sponsored by this organization (45)

An Open Label, Randomized, Two-Period, Single Oral Dose, Crossover BE Study of SITAGAVIA (100 mg) of the GPO, Thailand with Januvia of ORGANON PHARMA (UK) LIMITED, United Kingdom in Normal, Healthy, Adult Human Subjects under Fasting Conditions

Not yet recruiting

Nov 202330 participants

An open-label extension Phase 2 study, to evaluate the safety and immunogenicity of 10 mcg HXP-GPOVac vaccine boost in volunteers from study GPO NDV-HXP-S 202

Feb 2023280 participants

An Open Label, Randomized, Two-Treatment, Two-Period, Two-Sequence, Single Oral Dose, Crossover BE Study of EXITIN (10 mg) of the Government Pharmaceutical Organization, Thailand with Lexapro of H.LUNDBECK A/S, Denmark in Normal, Healthy, Adult Human Subjects under Fasting Conditions

Feb 202328 participants

An Open Label, Randomized, Two-Treatment, Four-Period, Crossover, Fully Replicate BE Study of AVASTAN (40 mg) (Atorvastatin 40 mg Tablets) of GPO, Thailand with LIPITOR (Atorvastatin 40 mg Tablets) of Pfizer Pharmaceuticals LLC, Puerto Rico, in Healthy Subjects under Fasting Conditions

Not yet recruiting

Nov 202242 participants

Phase 3 study, to evaluate the safety and immunogenicity of 10 mcg HXP-GPOVac COVID-19 vaccine boost in comparison to a viral vector-based COVID-19 vaccines

Enrolling By Invitation

Oct 20224,000 participants

An Open Label, Randomized, Two-Period, Single Oral Dose, Crossover Bioequivalence Study of ARIPAZ-5 (Aripiprazole 5 mg tablets) of the GPO, Thailand with ABILIFY (Aripiprazole 5 mg tablets) of Korea Otsuka Pharmaceutical Co., Ltd., Korea in Healthy, Adult Human Subjects under Fasting Conditions

Not yet recruiting

Aug 202252 participants

A Phase 2 Double-blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of 10 mcg HXP-GPOVac Vaccine in Healthy Volunteers

Aug 2022300 participants

An Open Label, Randomized, Two-Period, Single Oral Dose, Crossover Bioequivalence Study of RIBAROX (20 mg) (Rivaroxaban 20 mg tablets) of the GPO, Thailand with Xarelto (Rivaroxaban 20 mg tablets) of Bayer AG, Germany in Healthy, Adult Human Subjects under Fed Conditions

Not yet recruiting

Aug 202232 participants

Page 1 of 6

Approvals

Approvals by Agency

PHILIPPINES

Philippines FDA

3

Approvals

NPRA

National Pharmaceutical Regulatory Agency

5

Approvals

Recent Approvals

GPO-CurQmin Capsule

WELLS VITAMIN B1-B6-B12 TABLETS

IPODINE SOLUTION 10% W/V

Wellmex Hydrogen Peroxide 6% w/v Solution

GPO-L-One Tablet 500mg

26 January 2023

News

No news articles found

On this page

Overview
Clinical Trials45
Approvals8
News

Back to Organizations